PMGC Impasse

PMGC Holdings, formerly known as Elevai Labs, is a diversified holding company focused on biotechnology, precision manufacturing, and strategic investments. The company's primary biopharmaceutical subsidiary, Northstrive Biosciences, is advancing a pipeline of engineered probiotics, led by EL-22, which is designed to preserve muscle mass in patients undergoing weight loss treatments like GLP-1 receptor agonists. EL-22 utilizes a novel oral vaccine approach, employing genetically modified Lactobacillus casei to induce an immune response against myostatin, a negative regulator of muscle growth. Following the divestiture of its skincare business (formerly Elevai Skincare, now PMGC Impasse Corp) in early 2025, PMGC has pivoted toward high-value therapeutic assets and industrial operations. The company is publicly traded on the NASDAQ under the symbol ELAB.